TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04283617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensification of insulin regimen/Nutrition
Description: The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between \< 180 mg/dl at bedtime. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensification of insulin regimen/Nutrition
Description: The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between \< 180 mg/dl at bedtime. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.
Study: NCT04785443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.~Patients will then be followed during 6 months.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group
Description: During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.~Patients will then be followed during 6 months.
Study: NCT05000294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
Study: NCT05133024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: concentrated beetroot juice
Description: Nitrate supplementation; natural source of dietary nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: concentrated beetroot juice
Description: Nitrate supplementation; natural source of dietary nitrate
Study: NCT04846673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg + Alpha-lipoic acid 480mg
Description: Pregabalin qd + alpha-lipoic acid qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: pregabalin qd
Study: NCT06447558

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: palatal stimulation with a finger in premature infants
Description: Oral administration of breast milk droplets, palatal stimulation with a finger in premature infants
Study: NCT04906122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling.
Description: The research was planned as a randomized controlled study. Voluntary postpartum primiparous mothers who have recently given birth and their accompanying grandmothers will be randomly assigned to the intervention and control group. The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
Study: NCT06079788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotrophic Hormone
Description: For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
Study: NCT04895449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: i.m. vaccine administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: i.m. vaccine administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: i.m. vaccine administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: i.m. vaccine administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: i.m. vaccine administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: i.m. vaccine administration
Study: NCT04846673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Lipoic Acid 480mg
Description: alpha-lipoic acid qd
Study: NCT04957446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic
Description: Injectable implant containing microparticles of poly-L-lactic acid (PLLA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05201144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Oral Suspension
Description: Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volume of placebo
Study: NCT05644834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I'm Fully Empowered for Her (IFE4Her)
Description: IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
Study: NCT04210648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Mobile app for self-managing emotional dysregulation
Study: NCT06112665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG
Description: Patients receive Tofacitinib and Naproxene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: Patients receive Tofacitinib and Naproxene
Study: NCT06518356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Neurostimulation (tAN)
Description: The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Neurostimulation (tAN)
Description: The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Neurostimulation (tAN)
Description: The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).
Study: NCT05519098

Intervention type: DEVICE
Intervention: COLO-SW-1
Description: Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
Study: NCT06257550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE Intervention
Description: THRIVE Intervention includes:~1. Weekly Pulse Surveys~2. Adaptive culturally tailored messages~3. Personalized Dietitian Coaching~4. Produce Prescription FARMacy Mobile Market~5. Linkages to Social Services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: The Active Comparator arm will receive standard produce bags through our food is medicine partner, and will receive the linkages to needed social and health resources intervention components.
Study: NCT04978350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Workbook
Description: Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?
Study: NCT05765682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine Spinal
Description: spinal block using 60mg of mepivacaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Spinal
Description: spinal block using 10mg of bupivacaine
Study: NCT05976555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)
Description: This is dose level 0 (de-escalation).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)
Description: This is dose level 0 (de-escalation).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
Description: This is dose level 1, the starting dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
Description: This is dose level 1, the starting dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)
Description: This is dose level 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)
Description: This is dose level 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)
Description: This is dose level 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)
Description: This is dose level 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose
Description: The maximum tolerated dose is yet to be determined.
Study: NCT04608617

Intervention type: DEVICE
Intervention: Viz LVO (De Novo Number DEN170073)
Description: Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application.

Intervention type: OTHER
Intervention: Baseline Effectiveness Cohort
Description: No Intervention was performed for the pre-Viz group. Record review to establish operational metrics only occurred.
Study: NCT04755816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium intervention
Description: The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium intervention
Description: The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical worsening intervention
Description: The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical worsening intervention
Description: The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational content
Description: Standard heart failure educational information and a daily symptom survey.
Study: NCT04982237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv infusion
Study: NCT06474624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio Rehabilitation program
Description: A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio Rehabilitation program
Description: A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling for 20-30 minutes
Description: Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling a total of 4 cycles
Description: Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods.
Study: NCT06159088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Feihe Investigational Formula
Description: Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula
Description: Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding
Description: Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
Study: NCT06532643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: anti-CD20/CD30-CAR-T cells
Description: Each subject will be infused with single dose of anti-CD20/CD30-CAR-T cells. A classic 3+3 dose escalation will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
Study: NCT05599750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional hernia repair
Description: Participants will undergo incisional hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional hernia repair
Description: Participants will undergo incisional hernia repair
Study: NCT05400655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered subcutaneously.
Study: NCT06394037

Intervention type: PROCEDURE
Intervention: Active surveillance
Description: Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.
Study: NCT06446401

Intervention type: DRUG
Intervention: ADT + NHT + Docetaxel
Description: Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives the triple therapy, i.e. ADT, NHT and Docetaxel.

Intervention type: DRUG
Intervention: ADT + NHT
Description: Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives double therapy, i.e. they are receiving NHT and ADT, but not Docetaxel.